| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a9e6421e9257148abad101e1ce6c162 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K9-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06113 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-08 |
| filingDate |
2004-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e71806753758a64996a91f6c61f174a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8158eeb117e9ac2bb1387c7f30f1dff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aba4921a548e6145d1bb19cd97687a73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbe06ac61cbaa7c779a3d0f3c9065238 |
| publicationDate |
2005-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1574516-A1 |
| titleOfInvention |
Antithrombotic compound |
| abstract |
The present invention relates compounds of the formula An oligosaccharide-spacer-GpIIb/IIIa antagonist nwherein nthe oligosaccharide is a negatively charged oligosaccharide residue comprising four to twentynfive monosaccharide units, the charge being compensated by positively charged counterions,nand wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-IIInmediated) anti-Xa activity per se ; nthe spacer is a bond or an essentially pharmacologically inactive linking residue; nthe GpIIb/IIIa antagonist is a residue mimicking the RGD and/or K(QA)GD fragment ofnfibrinogen, typically comprising an optionally esterified carboxylate moiety and a basic moietynlocated within the residue at a distance of 10-20 Å from each other; nor a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof. n The compounds of the invention have antithrombotic activity and can be used in treating ornpreventing thrombotic diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007042470-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103917552-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007042469-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9556215-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2006301331-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103917552-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007042470-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012172104-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8183228-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007042469-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010065717-A1 |
| priorityDate |
2004-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |